

Chinese Journal of Pharmacovigilance ›› 2026, Vol. 23 ›› Issue (7): 829-834.
DOI: 10.19803/j.1672-8629.20260072
Previous Articles Next Articles
Zhang Chenlu, Li Mingqi, Wang Yinghe, Ma Yuehong*
Received:2026-01-21
Online:2026-07-15
Published:2026-07-16
CLC Number:
Zhang Chenlu, Li Mingqi, Wang Yinghe, Ma Yuehong. Research progress in signal pathways of traditional Chinese medicine in anti-liver fibrosis[J]. Chinese Journal of Pharmacovigilance, 2026, 23(7): 829-834.
| [1] Zhou Xin, Wang Zhi, He Xueru, et al.Research progress on potential anti-liver fibrosis drugs and target-related signaling pathways[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2023, 39(12): 2932-2941. [2] Meinian Onehealth Healthcare Holdings Co., Ltd., Zhongguancun Meinian Health Industry Research Institute. Blue Book of Big Data on Health Examinations2023(美年健康2023年度健康体检大数据蓝皮书)[EB/OL]. (2024-07-06)[2025-12-16]. https://max.book118.com/ html/2024/0626/7141112031006125.shtm. [3] Shi Meijie, Xiao Huanming, Xie Yubao, et al.Current status, challenges, and reflections on the prevention and treatment of chronic hepatitis B liver fibrosis with traditional Chinese medicine[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2023, 39(6): 1281-1286. [4] Zhou M, Wang J, Pan J, et al.Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy[J]. Nature Communications, 2023, 14(1): 3593. [5] Xin X, Cheng X, Zeng F, et al.The role of TGF-β/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis[J]. International Journal of Biological Sciences, 2024, 20(4): 1436. [6] Zhu W, Cui Y, Qiu J, et al.Exploring the therapeutic potential of TGF-β inhibitors for liver fibrosis: targeting multiple signaling pathways[J]. Journal of Clinical and Translational Hepatology, 2025, 13(7): 588-598. [7] Ghafouri-Fard S, Khanbabapour S A, Hussen B M, et al.Interplay between PI3K/AKT pathway and heart disorders[J]. Molecular Biology Reports, 2022, 49(10): 9767-9781. [8] Gao Xiaoyang, Zhao Xiaolu, Zhang Chunyan, et al.Quercetin induces apoptosis in hepatic stellate cells by regulating miR-146 and affecting the PI3K/Akt signaling pathway[J]. Journal of Southern Medical University(南方医科大学学报), 2023, 43(10): 1725-1733. [9] Du J J, Sun J C, Li N, et al.β-Arrestin2 deficiency attenuates oxidative stress in mouse hepatic fibrosis through modulation of NOX4[J]. Acta Pharmacologica Sinica, 2021, 42(7): 1090-1100. [10] Hao B, Sun R, Guo X, et al.NOX4-derived ROS promotes collagen I deposition in bronchial smooth muscle cells by activating noncanonical p38MAPK/akt-mediated TGF-β signaling[J]. Oxidative Medicine and Cellular Longevity, 2021, 2021: 6668971. [11] Zhang Chunyan, Zhao Xiaolu, Gao Xiaoyang, et al.Anti-liver fibrosis effect of Mongolian medicine Qiwei Qinggan powder based on NF-κB signaling pathway[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2024, 43(4): 296-303. [12] Guo Q, Jin Y, Chen X, et al.NF-κB in biology and targeted therapy: new insights and translational implications[J]. Signal Transduction and Targeted Therapy, 2024, 9(1): 53. [13] Ji Shaoxiu, Zhang Hengyao, Zhang Yuan, et al.Research progress on Notch signaling pathway in liver fibrosis[J]. Chinese Journal of Comparative Medicine(中国比较医学杂志), 2024, 34(6): 113-118. [14] Li Mingqi, Zhao Xiaolu, Gao Xiaoyang, et al.Research progress on the relationship between epithelial-mesenchymal transition and liver fibrosis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(4): 464-468, 472. [15] Shimizu M, Shibuya H.GSK3β regulates a novel β-catenin degradation pathway via the GID complex in wnt signaling[J]. Genes to Cells, 2025, 30(6): e70068. [16] Pan Xuwang, Ye Jianhong, Bao Jianfeng.Research progress on mechanisms of traditional Chinese medicine against liver fibrosis[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2025, 41(10): 1981-1987. [17] Chen X, Wang Y, Dou X, et al.Integrative metabolomics and proteomics reveal the effect and mechanism of Zi Qi decoction on alleviating liver fibrosis[J]. Scientific Reports, 2024, 14(1): 28943. [18] Chen Dongfang, Zheng Lihong.Research overview of traditional Chinese medicine regulating notch signaling pathway in the treatment of liver fibrosis[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases(中西医结合肝病杂志), 2025, 35(2): 261-264. [19] Wang Z, Li Y, Wang X, et al.Precision strike strategy for liver diseases trilogy with Xiao-Chai-Hu decoction: a meta-analysis with machine learning[J]. Phytomedicine, 2025, 142: 156796. [20] Ye Ziyu, He Xuedong, Zheng Yongjun, et al.Research progress on anti-liver fibrosis mechanism of active components from Ligustri Lucidi Fructus[J]. Chinese Traditional and Herbal Drugs(中草药), 2024, 55(4): 1389-1396. [21] Zhou L H, Chen X.Geniposide inhibits hepatic fibrosis and hepatic stellate cell activation through blocking the TGF-β1/smad signaling pathway[J]. Acta Physiologica Sinica, 2022, 74(2): 217-224. [22] Yuan X, Gong Z, Wang B, et al.Astragaloside inhibits hepatic fibrosis by modulation of TGF-β1/smad signaling pathway[J]. Evidence-Based Complementary and Alternative Medicine, 2018, 2018: 3231647. [23] Yao Q Y, Xu B L, Wang J Y, et al.Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats[J]. BMC Complementary Medicine and Therapies, 2012, 12: 196. [24] Liu T, Xu L, Wang C, et al.Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-β1/smads pathway through shikonin[J]. Journal of Gastroenterology and Hepatology, 2019, 34(1): 263-276. [25] Qiao Jingyi, Li Hanwei, Chen Jinxiang, et al.Network pharmacology analysis and experimental validation of anti-liver fibrosis effect of Mori Fructus[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2024, 43(1): 62-69. [26] Hu Xinxin, Xu Shengjie, Meng Xiaofan, et al.Research progress on traditional Chinese medicine monomers targeting TGF-β1/Smad signaling pathway in preventing and treating renal interstitial fibrosis[J]. Chinese Journal of Integrated Traditional and Western Nephrology(中国中西医结合肾病杂志), 2024, 25(4): 365-368. [27] Wang Xinmeng, Xiong Wei, Zi Jiaji.Research progress on the anti-fibrotic mechanism of paeoniflorin[J]. Youjiang Medical Journal(右江医学), 2024, 52(7): 647-650. [28] Huang B H, Guo Z W, Lyu B H, et al.A role for curcumin in preventing liver fibrosis in animals: a systematic review and meta-analysis[J]. Frontiers in Pharmacology, 2024, 15: 1501570. [29] Huang S P, Zhang Z C, Chen Y, et al.Review of Chinese medicine intervention in PI3K/AKT pathway to regulate fibrosis[J]. Medicine, 2025, 104(28): e42957. [30] Lin X, Wei Y, Li Y, et al.Tormentic acid ameliorates hepatic fibrosis in vivo by inhibiting glycerophospholipids metabolism and PI3K/AKT/mTOR and NF-κB pathways: based on transcriptomics and metabolomics[J]. Frontiers in Pharmacology, 2022, 13: 918579. [31] Pan C, Li L, Li G.Artesunate inhibits anti-liver fibrosis by blocking the epithelial-mesenchymal transition and regulating the C-jun N-terminal kinase pathway[J]. Indian Journal of Pharmaceutical Sciences, 2022, 84(6): 1520-1528. [32] Lang Z, Li Y, Lin L, et al.Hepatocyte-derived exosomal miR-146a-5p inhibits hepatic stellate cell EMT process: a crosstalk between hepatocytes and hepatic stellate cells[J]. Cell Death Discovery, 2023, 9(1): 304. [33] Le T V, Phan-Thi H T, Huynh-Thi M X, et al. Autophagy inhibitor chloroquine downmodulates hepatic stellate cell activation and liver damage in bile-duct-ligated mice[J]. Cells, 2023, 12(7): 1025. [34] Wang S, Qin D, Xu A, et al.Upregulation of ATG9b by propranolol promo-tes autophagic cell death of hepatic stellate cells to improve liver fibrosis[J]. Journal of Cellular and Molecular Medicine, 2024, 28(2): e18076. [35] Yang Xing, Wang Zhen, Liu Jiangkai, et al.Research progress on curcumin against liver fibrosis based on cellular signaling pathways[J]. Chinese Traditional Patent Medicine(中成药), 2023, 45(5): 1571-1576. [36] Wang Y, Ma Z, Peng W, et al.3,5,6,7,8,3',4'-heptamethoxyflavonoid inhibits TGF-β1-induced epithelial-mesenchymal transition by regulating oxidative stress and autophagy through MEK/ERK/PI3K/AKT/mTOR signaling pathway[J]. Scientific Reports, 2025, 15(1): 4567. [37] Zhang Y, Hua L, Lin C, et al.Pien-Tze-Huang alleviates CCl4-induced liver fibrosis through the inhibition of HSC autophagy and the TGF-β1/Smad2 pathway[J]. Frontiers in Pharmacology, 2022, 13: 937484. [38] Zheng Y, Zhao T, Wang J, et al.Curcumol alleviates liver fibrosis through inducing autophagy and ferroptosis in hepatic stellate cells[J]. FASEB Journal, 2022, 36(12): e22665. [39] Gerami H, Mozaffari-Khosravi H, Mansour A, et al.Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial[J]. Scientific Reports, 2025, 15(1): 38043. |
| [1] | Li Yajing, Chen Tengfei, Wang Xuerui, Xu Xiaolong, Liu Qingquan. Mechanisms of β-Sitosterol against sepsis-induced coagulopathy based on data mining and network pharmacology [J]. Chinese Journal of Pharmacovigilance, 2026, 23(7): 733-738. |
| [2] | Wei Minghui, Liu Fangbing, Li Xiangming, Li Jianying, Zhang Jiaru, Yin Dongjie, Ren Zhongjie, Guo Ying, Wang Minjie, Xue Mingming. Mechanisms of action of Siwei Tumuxiang powder against hypertensive myocardial hypertrophy in rats based on transcriptomics [J]. Chinese Journal of Pharmacovigilance, 2026, 23(7): 767-774. |
| [3] | BAI Xue, LI Xueli. Research Progress in Roles of Extracellular Vesicles in Thromboinflammation in Ischemic Cardio-Cerebrovascular Diseases Treated with Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 607-612. |
| [4] | LI Yanjun, LIU Chengxiang, TANG Bo, LIU Yi, ZHANG Jiuliang, JIANG Guochen, BAI Xue. Roles of Butu Decoction in Improving Heart Failure in Rats by Activating AKT/Bcl-2 Signaling Axis and Inhibiting Cardiomyocyte Apoptosis [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 621-629. |
| [5] | NIU Yuanfei, LIU Meiting, RONG Wenshuang, MA Lina, GU Yuanyuan, ZHANG Lichun, HOU Hongping, YANG Mengyuan, ZHENG Changhui, FU Yao, HE Ting, ZHAO Wei, WANG Lianmei, CAO Junling. Research Progress in the Pathogenesis of Acute Lung Injury and Interventions with Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 714-719. |
| [6] | LI Yaolei, CHENG Xianlong, LIN Yongqiang, LIU Jing, WEI Feng. Applications of Artificial Intelligence in Research on Traditional Chinese Medicine Metabolomics [J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 481-486. |
| [7] | YAO Ziying, SHEN Mengting, MA Congyu, HU Zhaoliang, ZHAO Yi, MENG Changhong, KANG An, WANG Yuxin. Evaluation of Anaphylactoid Reactions Induced by Traditional Chinese Medicine Injections Based on in vitro and in vivo Models [J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 513-518. |
| [8] | WU Yanlin, YU Sisi, WEN Miao, LI Huimin, YANG Zean, ZHANG Yuan, HE Qing. Evaluation of Allergic Reactions Caused by Indicator Components of Shuanghuanglian Injection [J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 539-546. |
| [9] | WEI Wei, QUAN Qinbo, WANG Linghua, TIAN Yuejie, HUANG Lin, LI Na, WANG Weibo. Visualization of Real-World Adverse Drug Reaction Based on a Traditional Chinese Medicine Preparation as Empirical Evidence [J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 564-568. |
| [10] | PENG Lili, FAN Yan, TIAN Chunhua, XIAO Suping. Research Progress in Effects of Traditional Chinese Medicine on Neural Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 585-589. |
| [11] | LIU Chenyue, MA Lin, LI Chunying, LI Fang, HAN Jiayin, WANG Lianmei, LI Xu, YI Yan, ZHAO Yong, TIAN Jingzhuo, ZHANG Yushi, CUI Shuang, MENG Jing, XIAO Wei, LIANG Aihua. Standard Operating Procedures for Detecting Pseudo-Allergic Reactions to Traditional Chinese Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 361-367. |
| [12] | QI Ling, ZHANG Xianxie, CHEN Xitai, HUANG Tianke, LI Fang, CHEN Liping, TA Yanling, MA Zengchun. Establishment and Evaluation of an Animal Model for High-Altitude Daytime Dysfunction with Syndrome of Phlegm-Turbidity Obstructing the Orifices [J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 375-382. |
| [13] | LIANG Xiao, XU Xiaolong, BAI Yinglu, ZHANG Xuemin, LIU Qingquan. Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Adult Brucellosis: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 450-455. |
| [14] | MA Ningning, ZHU Lin, XIAN Junying, FENG Xue, ZHANG Caijuan, WANG Dunfang, LIU Haifan, LIU Bin, LIU Jianyao, LI Yuehua, YANG Weipeng. Pathogenesis in a Rat Model of Osteosarcopenia Based on Network Pharmacology and Experimental Validation [J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 155-161. |
| [15] | LI Yaolei, CHENG Xianlong, LIN Yongqiang, LIU Jing, WEI Feng. Key Technologies for Research on Speciation and Valence of Elements in Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 174-180. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||